Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PARD $0.14 0.0400 +40.00%
TLOG $2.71 0.3600 +15.32%
EXEL $6.62 0.5000 +8.17%
INCY $109.74 5.7600 +5.54%
REGN $580.94 26.6700 +4.81%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

NYMX $2.38 -0.1800 -7.03%
GALT $2.65 -0.1300 -4.68%
CTIX $2.41 -0.1000 -3.98%
ONCS $5.79 -0.1900 -3.18%
ADXS $15.35 -0.5000 -3.15%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Next > | Last >>

Study Explores Protein's Role in Inflammation-Associated Cancer

(VICC) July 23, 2015 - A protein that transports the micronutrient selenium and has antioxidant functions may protect against colitis-associated carcinoma — colon cancer that develops in patients with inflammatory bowel disease, according to a new Vanderbilt-led study.
read article 



Six New Gene Locations Identified for Colorectal Cancer Risk

(University of Washington/SPH) July 21, 2015 - An international team of researchers has identified six new locations in the human genome where people could be more at risk for colorectal cancer.
read article 



Calmangafodipir May Reduce Chemo-Induced Neuropathy

(Medscape Medical News) July 23, 2015 - Calmangafodipir (PledOx, PledPharma) reduced the frequency, onset, and duration of chemotherapy-induced peripheral neuropathy (CINP) in patients with metastatic colorectal cancer undergoing chemotherapy containing oxaliplatin (Eloxatin, sanofi-aventis), for which CINP is a dose-limiting side effect.
read article (free registration required) 



Stem Cell Transplantation for Children with Rare Form of Leukemia Improves Outcomes

(CHLA) July 23, 2015 - Researchers in the Division of Hematology, Oncology and Blood & Marrow Transplantation at Children's Hospital Los Angeles have shown greatly improved outcomes in using stem cell transplantation to treat patients with a serious but very rare form of chronic blood cancer called juvenile myelomonocytic leukemia (JMML).
read press release 



Poor Survival in Multiple Myeloma Patients Linked to Genetic Variation

(Huntsman Cancer Institute) July 22, 2015 - As part of a multi-institutional effort, researchers with Huntsman Cancer Institute at the University of Utah have found that multiple myeloma patients with a genetic variation in the gene FOPNL die on average 1-3 years sooner than patients without it.
read press release 



Osteoporosis Drug Could Benefit Postmenopausal Women with Breast Cancer

(Cancer Research [UK]) July 23, 2015 - The study published in The Lancet, showed that the drugs – called bisphosphonates – reduced the risk of breast cancer coming back, as well as significantly reducing the risk of death, in women diagnosed after their menopause with early-stage breast cancer.
read article 



FDA Seeks More Clinical Evidence On Sunesis Pharma Cancer Drug

(Reuters) July 23, 2015 - Sunesis Pharmaceuticals Inc said the U.S. Food and Drug Administration called for more clinical evidence before considering approval for its cancer drug, sending the company's shares down 60 percent in after-market trading.
read article 



Sunesis Dives as Company Plans to Focus on Getting Qinprezo Approved in EU; FDA Wants New Data

(Fox Business/Associated Press) July 23, 2015 - Shares of Sunesis Pharmaceuticals plunged in aftermarket trading Thursday after the company said it will focus on trying to get its blood cancer drug Qinprezo on the market in Europe because regulators in the U.S. won't approve it based on available data.
read article 



Novartis Combination Therapy Tafinlar® and Mekinist® Achieves Important EU and US Regulatory Milestones

(Novartis) July 24, 2015 - Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
read corporate press release 



Two Generic Drugs Shown to Reduce Breast Cancer Deaths

(CBS News) July 24, 2015 - There's new evidence that two inexpensive generic drugs can improve survival rates for women who develop breast cancer after menopause.
read article 



Benefit of End-Stage Chemotherapy Is Questioned

(New York Times) July 23, 2015 - It is an excruciating question for cancer patients with a prognosis of only months to live. Should they try another round of chemotherapy?
read article 



With Anthem-Cigna Deal Near, the Health Insurance Industry Is Headed Toward a ‘Big Three’

(Washington Post/Wonkblog) July 22, 2015 - The nation's big five health insurers will become the big three, with a $48 billion merger imminent between Cigna and Anthem, according to the Wall Street Journal.
read article (free registration required) 



Younger Adults With Alzheimer's Are Key to Drug Search

(NPR/Shots blog) July 23, 2015 - A very rare genetic mutation causes some people to develop Alzheimer's in their 30s. It also makes these people the ideal candidates for tests of potential Alzheimer's drugs.
read article 



Funds Join Campaign to Pressure Pharma to Disclose Trial Data

(Wall Street Journal/Pharmalot blog) July 22, 2015 - In an unprecedented move, a group of 85 asset managers and pension funds is teaming with a U.K. non-profit campaign to pressure drug makers to disclose clinical trial data.
read article (paid subscription required) 



Main Fund for Medicare Program to Run Out of Money in 2030: Trustees

(Reuters) July 22, 2015 - A slowdown in healthcare spending has shored up the funding outlook for the federal program that pays elderly Americans' hospital bills, trustees of the program said on Wednesday.
read article 



The American Society of Hematology Honors John C. Byrd, MD, with 2015 William Dameshek Prize

(ASH) July 23, 2015 - The American Society of Hematology will present the 2015 William Dameshek Prize to John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) for his contributions to the development of transformative treatments for chronic lymphocytic leukemia (CLL), most notably rituximab and ibrutinib.
read press release 



The American Society of Hematology Honors Life, Accomplishments of Aaron J. Marcus, MD, with Wallace H. Coulter Award for Lifetime Achievement in Hematology

(ASH) July 23, 2015 - The American Society of Hematology (ASH) will recognize the late Aaron Marcus, MD, of Weill Cornell Medical College in New York and the VA New York Harbor Healthcare System with the 2015 Wallace H. Coulter Award for Lifetime Achievement in Hematology.
read press release 



Proposed Medicare Physician Payment Cuts for 2016 Threaten Access to Community-Based Radiation Therapy

(ASTRO) July 22, 2015 - The American Society for Radiation Oncology (ASTRO) is concerned about proposed additional payment cuts to radiation therapy detailed in the Centers for Medicare and Medicaid Services’ (CMS) proposed Medicare Physician Fee Schedule (MPFS), released July 8, 2015, which will take effect on January 1, 2016.
read press release 



Inovio Pharmaceuticals and European Organization for Research and Treatment of Cancer to Collaborate on Large Phase II Cervical Cancer Trial

(Yahoo! Finance) July 23, 2015 - Inovio Pharmaceuticals, Inc. announced today that it is collaborating with the European Organization for Research and Treatment of Cancer (EORTC) to evaluate Inovio's immunotherapy, INO-3112, in combination with traditional chemo-radiotherapy for the treatment of patients with locally advanced stage cervical cancer.
read article 



Roche Readies New Drugs in Two-Year Window Before Copycats Hit

(Reuters) July 23, 2015 - Switzerland's Roche is lining up more new drugs to drive sales in a two-year window before cheap copycats of its biotech medicines hit the market, including a promising cancer immunotherapy it hopes to launch by late 2016.
read article 



Newsweek Health: Top Cancer Doctors 2015

(Newsweek) July 23, 2015 - 'Newsweek,' in conjunction with Castle Connolly Medical Ltd. is proud to present the list of the 'Top Cancer Doctors 2015' for the United States.
read article (free registration required) 



OPKO's Prostate Cancer Hit

(Forbes) July 23, 2015 - On June 26, 2015, 4Kscore was included in the National Comprehensive Cancer Network (NCCN) guidelines for early detection of prostate cancer.
read article 



Baxalta Completes ONCASPAR Portfolio Acquisition, Aims to Broaden Patient Access to Leading Treatment for Leukemia

(StreetInsider) July 23, 2015 - Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced that the company has completed the acquisition of the ONCASPAR (pegaspargase) portfolio from Sigma-Tau Finanziaria S.p.A.
read article 



Marijuana Is a Wonder Drug When It Comes to the Horrors of Chemo

(Newsweek) July 22, 2015 - A growing number of cancer patients and oncologists view the drug as a viable alternative for managing chemotherapy’s effects, as well as some of the physical and emotional health consequences of cancer, such as bone pain, anxiety and depression.
read article (free registration required) 



Researchers Decode Molecular Action of Combination Therapy for a Deadly Thyroid Cancer

(Mayo Clinic) July 23, 2015 - In their bid to find the best combination of therapies to treat anaplastic thyroid cancer (ATC), researchers on Mayo Clinic’s Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.
read press release